The performance of zotarolimus-eluting stents (Medtronic Inc., Santa Clara, CA, USA) versus other limus-eluting stents (LES) and the possible improvements of Resolute zotarolimus-eluting stents (R-ZES) versus Endeavor zotarolimus-eluting stents (E-ZES) still remain to be defined. We sought to evaluate efficacy and safety of two zotarolimus-eluting stent generations versus other LES and to compare R-ZES versus E-ZES. Methods: We undertook a meta-analysis of trials in which patients were randomly assigned to percutaneous coronary interventions (PCI) with R-ZES versus LES or with E-ZES versus LES as well as an indirect comparison of R-ZES versus E-ZES, with LES as common comparator. The primary efficacy endpoint was ischemia-driven target vessel revascularization (ID-TVR); the primary safety endpoints were cardiac death and cumulative definite/probable stent thrombosis (ST). Results: Overall, 13,709 patients were assigned to PCI with R-ZES versus LES (nϭ 7,185) or with E-ZES versus LES (nϭ 6,524). The risk of ID-TVR (odds ratio [95% confidence interval]ϭ 1.06 [0.90-1.25], pϭ 0.47), cardiac death (0.99 [0.69-1.42], pϭ 0.96) and ST (1.18 [0.68-2.03], pϭ 0.56) did not differ between R-ZES and LES. Patients receiving E-ZES were more likely to undergo ID-TVR as compared to those receiving LES (1.95 [1.40-2.73], pϽ0.0001). Cardiac death (1.02 [0.54-1.91], pϭ 0.96) and ST (1.10 [0.50-2.44], pϭ 0.81) were similar between E-ZES and LES. At indirect comparison, PCI with R-ZES versus E-ZES reduced the risk of ID-TVR (0.54 [0.37-0.78], pϭ 0.001), without increasing cardiac death (0.97 [0.46-2.00], pϭ 0.93) and ST (1.07 [0.40-2.80], pϭ 0.88).
Background: Vascular Inflammation plays a fundamental role in the process of neointimal formation following coronary stent implantation. Drug-eluting stents (DES) improve the efficacy of percutaneous coronary intervention by modulating vascular inflammation. We aimed to evaluate the vascular inflammation profile following coronary implantation of a novel stent comprising an abluminal biodegradable Everolimus-eluting coating on the Element stent platform (SYNERGY) compared to an identical bare metal stent control (BMSϭ Element stent). Methods: BMS (Element, nϭ6) and SYNERGY (nϭ6) stents were implanted in nine 8-month-old FH swine. Each coronary target site was predilated with an angioplasty balloon prior to stent placement. At 30 days stents were analyzed with optical coherence tomography (OCT) and then harvested for histological analysis and immunohistochemistry (MAC387: Macrophages; CD3: T-cells lymphocytes). Para strut leukocyte (PSL), Foamy macrophage infiltration (FMI) and adventitial inflammation (AI) were evaluated in a semi-quantitative score. Results: Both OCT (neointimal area; SYNERGY, 3.68Ϯ0.8 mm2 vs. BMS, 5.7Ϯ0.8 mm2, 35% reduction) and histology (neointimal area; SYNERGYϭ3.18Ϯ0.73 mm2 vs. BMSϭ 5.93Ϯ0.78 mm2, 46% reduction) demonstrated a significant reduction in neointimal proliferation in the SYNERGY group. The SYNERGY stent exhibited significant reduction in PSL (0.33Ϯ0.69) compared to BMS (2.39Ϯ0.7, pϽ0.001). The neointimal area occupied by foam cells was significantly greater in BMS (0.57Ϯ0.53 mm2) compared to SYNERGY group (0.28Ϯ0.35 mm2). Consistently, FMI score was also decreased in SYNERGY (0.83Ϯ0.79) compared to BMS (2.44Ϯ2.06, pϽ0.001). The AI score, did not showed significant differences between the studied groups (SYNERGY 1.33Ϯ1.46, BMS 1.94Ϯ1.55; pϭ0.15).
Conclusions:
The abluminal-only Everolimus eluting SYNERGY stent demonstrated suppression of neointimal formation and vascular inflammatory response compared to an identical bare metal stent platform. The absence of polymer beyond the drug delivery period creates the potential to reduce DAPT duration while maintaining best-in-class DES efficacy.
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